Fund Holdings — Avidity Partners Management LP

Total Portfolio Value:
$427.95M
Total Bought:
$16.64M
Total Sold:
$166.91M
Net Transaction:
-$150.27M
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Dianthus Therapeutics, Inc.(DNTH)2,104,1841,899,593-204,591$205.12M$167.26M39.08%-$37.86M
CG Oncology, Inc.(CGON)1,398,9481,348,948-50,000$99.40M$95.63M22.35%-$3.77M
Oruka Therapeutics, Inc.(ORKA)760,424785,424+25,000$72.37M$65.42M15.29%-$6.95M
Jade Biosciences Inc1,700,7082,000,000+299,292$37.79M$28.10M6.57%-$9.69M
Enliven Therapeutics Inc550,000550,0000$27.91M$25.21M5.89%-$2.70M
Perspective Therapeutics, Inc.(CATX)6,299,9996,067,999-232,000$21.48M$16.69M3.90%-$4.80M
Aktis Oncology, Inc.(AKTS)484,200484,2000$15.61M$9.43M2.20%-$6.18M
Immunic, Inc.(IMUX)669,941669,9410$10.30M$6.23M1.46%-$4.07M
Mobia Med Inc798,282324,676-473,606$10.70M$3.07M0.72%-$7.63M
Palvella Therapeutics, Inc.(PVLA)70,00020,000-50,000$10.70M$2.76M0.64%-$7.94M
Nuvectis Pharma, Inc.(NVCT)200,000100,415-99,585$3.68M$2.12M0.50%-$1.56M
Satellos Bioscience Inc.(MSLE)387,769164,019-223,750$3.01M$1.39M0.33%-$1.62M
Context Therapeutics Inc.(CNTX)4,998,2674,060,254-938,013$2.77M$1.22M0.29%-$1.55M
Karyopharm Therapeutics Inc.(KPTI)924,487884,900-39,587$9.03M$1.08M0.25%-$7.95M
Senseonics Holdings, Inc.(SENS)1,600,000100,000-1,500,000$9.09M$1.02M0.24%-$8.07M
Scynexis Inc260,206153,613-106,593$1.06M$758.8K0.18%-$300.2K
Avalyn Pharmaceuticals Inc60,00020,000-40,000$1.98M$569.8K0.13%-$1.41M
Abbott Laboratories10,0000-10,000$907.4K$0—-$907.4K
Alamar Biosciences Inc110,0000-110,000$2.98M$0—-$2.98M
Boston Scientific Corporation(BSX)80,0000-80,000$3.41M$0—-$3.41M
BridgeBio Oncology Therapeutics, Inc.(BBOT)43,8530-43,853$334.2K$0—-$334.2K
BridgeBio Pharma, Inc.(BBIO)10,0000-10,000$744.8K$0—-$744.8K
Charles River Laboratories International, Inc.(CRL)10,0000-10,000$2.27M$0—-$2.27M
Corvus Pharmaceuticals, Inc.(CRVS)80,0000-80,000$1.20M$0—-$1.20M
DexCom, Inc.(DXCM)100,0000-100,000$6.74M$0—-$6.74M
Encompass Health Corporation(EHC)42,0000-42,000$4.25M$0—-$4.25M
Evommune, Inc.(EVMN)75,0000-75,000$996.8K$0—-$996.8K
Genmab A/SADS(GMAB)50,0000-50,000$1.37M$0—-$1.37M
Gilead Sciences, Inc.(GILD)20,0000-20,000$2.53M$0—-$2.53M
Insulet Corporation(PODD)24,0000-24,000$3.65M$0—-$3.65M
Intellia Therapeutics, Inc.(NTLA)75,0000-75,000$1.27M$0—-$1.27M
Kailera Therapeutics Inc80,0000-80,000$1.76M$0—-$1.76M
Legend Biotech CorporationADS(LEGN)15,0000-15,000$433.2K$0—-$433.2K
Medtronic plcSHS(MDT)70,0000-70,000$5.48M$0—-$5.48M
Oddity Tech LtdCL A
SHS CL A
70,0000-70,000$1.06M$0—-$1.06M
Peloton Interactive, Inc.CL A(PTON)100,0000-100,000$591.0K$0—-$591.0K
Phathom Pharmaceuticals, Inc.(PHAT)200,0000-200,000$2.17M$0—-$2.17M
Repligen Corporation(RGEN)77,8000-77,800$10.62M$0—-$10.62M
Savara Inc.(SVRA)50,0000-50,000$308.0K$0—-$308.0K
Structure Therapeutics IncADS98,0000-98,000$5.26M$0—-$5.26M
Tempus AI, Inc.CL A(TEM)105,0000-105,000$6.08M$0—-$6.08M
Tenax Therapeutics, Inc.(TENX)265,9340-265,934$3.87M$0—-$3.87M
Teva Pharmaceutical Industries LimitedADS(TEVA)200,0000-200,000$6.78M$0—-$6.78M
Trevi Therapeutics, Inc.(TRVI)6,6600-6,660$124.2K$0—-$124.2K
Vir Biotechnology, Inc.(VIR)519,3000-519,300$5.29M$0—-$5.29M
Page 1 of 1
Avidity Partners Management LP — 13F Holdings — Q3 2026 | TickerTrail